Aurobindo Pharma USA Completes Acquisition of Lannett Company
1 min read Updated on 30 Jun 2026, 10:02 AM
Reviewed bySuketu GScanX News Team
Add as a preferred source on Google
AI Summary
Aurobindo Pharma USA Inc, a wholly owned subsidiary of Aurobindo Pharma Limited, has completed the acquisition of Lannett Company, Inc., USA, effective June 29, 2026, following U.S. Federal Trade Commission approval on June 18, 2026. Lannett will now operate as Lannett Company LLC, with over 400 employees joining the organization to strengthen operational capabilities and enhance availability of essential medicines
powered by
*this image is generated using AI for illustrative purposes only
Aurobindo Pharma USA Inc, a wholly owned subsidiary of Aurobindo Pharma Limited, has completed the acquisition of Lannett Company, Inc., USA. The transaction received approval from the U.S. Federal Trade Commission on June 18, 2026, concluding the purchase from Lannett Seller Holdco, Inc
Effective June 29, 2026, Lannett has become a wholly owned subsidiary of Aurobindo Pharma USA Inc and will operate as Lannett Company LLC. The integration process has commenced immediately, with a focus on ensuring uninterrupted access to critical medications and maintaining relationships with partners
The acquisition adds more than 400 Lannett employees to the organization, strengthening its talent base and operational capabilities. The company aims to combine reiver long-term value to patients and stakeholders
Aurobindo Pharma Limited acknowledged the leadership of Lannett’s management team for their role in enabling a smooth transition. The disclosure was made to the National Stock Exchange of India Limited and BSE Limited under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
Key Transaction Timeline
The following table outlines the key milestones in the completion of the acquisition:
| Key Event | Date |
|---|---|
| U.S. Federal Trade Commission Approval | June 18, 2026 |
| Acquisition Effective Date | June 29, 2026 |
Historical Stock Returns for Aurobindo Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.40% | +5.18% | +10.01% | +30.76% | +38.28% | +62.24% |
What specific cost synergies does Aurobindo Pharma expect to realize from the integration of Lannett’s operations?
How will this acquisition impact Aurobindo Pharma’s market share in the U.S. generic pharmaceutical sector?
What are the anticipated challenges in merging the corporate cultures and operational systems of the two companies?
Aurobindo PharmaView Company InsightsView All News
18
